Phase 3 MagnetisMM-32 Trial Results: Elrexfio (Elranatamab) Monotherapy Shows Statistically Significant PFS Benefit vs Three Standard Regimens in Relapsed/Refractory Myeloma Read more about Phase 3 MagnetisMM-32 Trial Results: Elrexfio (Elranatamab) Monotherapy Shows Statistically Significant PFS Benefit vs Three Standard Regimens in Relapsed/Refractory MyelomaAdd new comment
The International Myeloma Foundation Plays a Role in the Introduction of the CARE for Blood Cancer Act (H.R. 10858) Read more about The International Myeloma Foundation Plays a Role in the Introduction of the CARE for Blood Cancer Act (H.R. 10858)Add new comment
October 2026 – Myeloma News from the Journals Read more about October 2026 – Myeloma News from the JournalsAdd new comment
European Commission Approves Expanded Indication for Teclistamab Monotherapy as Treatment for Relapsed/Refractory Myeloma Read more about European Commission Approves Expanded Indication for Teclistamab Monotherapy as Treatment for Relapsed/Refractory Myeloma Add new comment
The International Myeloma Foundation Launches US Myeloma Network to Accelerate Clinical Trials, Expand Access, and Improve Patient Care Read more about The International Myeloma Foundation Launches US Myeloma Network to Accelerate Clinical Trials, Expand Access, and Improve Patient Care Add new comment
CHMP Recommends Earlier-Line Use of Talvey (Talquetamab) Plus Daratumumab for Relapsed/Refractory Myeloma Read more about CHMP Recommends Earlier-Line Use of Talvey (Talquetamab) Plus Daratumumab for Relapsed/Refractory Myeloma Add new comment
Dr. Wee Joo Chng to Receive Asian Myeloma Network Distinguished Service Award at the 10th AMN Summit in Shanghai Read more about Dr. Wee Joo Chng to Receive Asian Myeloma Network Distinguished Service Award at the 10th AMN Summit in ShanghaiAdd new comment
Phase 3 EXCALIBER-RRMM Trial Results: Zenbexus (Iberdomide) in Combination with Daratumumab and Dexamethasone Showed Longer Progression-Free Survival vs Standard of Care in Relapsed/Refractory Myeloma Read more about Phase 3 EXCALIBER-RRMM Trial Results: Zenbexus (Iberdomide) in Combination with Daratumumab and Dexamethasone Showed Longer Progression-Free Survival vs Standard of Care in Relapsed/Refractory MyelomaAdd new comment
